| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2004;35:1073.)
© 2004 American Heart Association, Inc.
Original Contributions |
From the Centre for Clinical Studies (M.H, C.K., E.H., T.T.-K.) and Institute and Outpatient Department for Clinical Metabolic Research (F.S.), Dresden Technical University, Dresden, Germany; Research Centre-CHUM-Hotel-Dieu (J.L.C.), Montreal, Canada.
Correspondence to Prof M. Hanefeld, Zentrum für Klinische Studien GWT der Technischen Universität Dresden, Fiedlerstr. 34, 01307 Dresden, Germany. E-mail hanefeld{at}gwt-tud.de
Background and Purpose Impaired glucose tolerance (IGT)a prediabetic stateis an important risk factor for atherosclerosis. Acarbose, an
-glucosidase inhibitor, was shown in the placebo-controlled prospective study to prevent noninsulin-dependent diabetes mellitus (STOP-NIDDM) trial to reduce the risk of diabetes by 36% in IGT subjects. This article reports on a placebo-controlled subgroup analysis of the STOP-NIDDM study to examine the efficacy of acarbose to slow progression of intima-media thickness (IMT) in subjects with IGT.
Methods One hundred thirty-two IGT subjects were randomized to placebo (n=66) or acarbose (n=66) 100 mg 3 times daily; the study duration was at least 3 years, mean follow-up time 3.9 (SD 0.6) years. Carotid IMT was determined at study entry and the end of the trial. The intent-to-treat analysis included 56 subjects in the acarbose and 59 in the control group who had a baseline and endpoint measurement.
Results A significant reduction of the progression of IMTmean was observed in the acarbose group versus placebo. After an average time of 3.9 years, IMTmean increased by 0.02 (0.07) mm in the acarbose group versus 0.05 (0.06) mm in the placebo group (P=0.027). The annual increase of IMTmean was reduced by
50% in the acarbose group versus placebo. Multiple linear regression revealed IMT progression as significantly related to acarbose intake.
Conclusions Acarbose slows progression of IMT in IGT subjects, a high-risk population for diabetes and atherosclerosis. This is the first placebo-controlled prospective subgroup analysis, demonstrating that counterbalancing of postprandial hyperglycemia may be vasoprotective.
Key Words: acarbose glucose intolerance intima-media thickness hyperglycemia ultrasonography
This article has been cited by other articles:
![]() |
K. C. Maki, M. L. Carson, M. P. Miller, M. Turowski, M. Bell, D. M. Wilder, T. M. Rains, and M. S. Reeves Hydroxypropylmethylcellulose and Methylcellulose Consumption Reduce Postprandial Insulinemia in Overweight and Obese Men and Women J. Nutr., February 1, 2008; 138(2): 292 - 296. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Milicevic, I. Raz, S. D. Beattie, B. N. Campaigne, S. Sarwat, E. Gromniak, I. Kowalska, E. Galic, M. Tan, and M. Hanefeld Natural History of Cardiovascular Disease in Patients With Diabetes: Role of hyperglycemia Diabetes Care, February 1, 2008; 31(Supplement_2): S155 - S160. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Mita, H. Watada, T. Shimizu, Y. Tamura, F. Sato, T. Watanabe, J. B. Choi, T. Hirose, Y. Tanaka, and R. Kawamori Nateglinide Reduces Carotid Intima-Media Thickening in Type 2 Diabetic Patients Under Good Glycemic Control Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2456 - 2462. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Maki, M. L. Carson, M. P. Miller, M. Turowski, M. Bell, D. M. Wilder, and M. S. Reeves High-Viscosity Hydroxypropylmethylcellulose Blunts Postprandial Glucose and Insulin Responses Diabetes Care, May 1, 2007; 30(5): 1039 - 1043. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. T. Bloomgarden Glycemic treatment in type 1 and type 2 diabetes. Diabetes Care, November 1, 2006; 29(11): 2549 - 2555. [Full Text] [PDF] |
||||
![]() |
H. Yokoyama, N. Katakami, and Y. Yamasaki Recent Advances of Intervention to Inhibit Progression of Carotid Intima-Media Thickness in Patients With Type 2 Diabetes Mellitus Stroke, September 1, 2006; 37(9): 2420 - 2427. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Crouse III Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art J. Lipid Res., August 1, 2006; 47(8): 1677 - 1699. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Cavalot, A. Petrelli, M. Traversa, K. Bonomo, E. Fiora, M. Conti, G. Anfossi, G. Costa, and M. Trovati Postprandial Blood Glucose Is a Stronger Predictor of Cardiovascular Events Than Fasting Blood Glucose in Type 2 Diabetes Mellitus, Particularly in Women: Lessons from the San Luigi Gonzaga Diabetes Study J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 813 - 819. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Novoa, M. Boronat, P. Saavedra, J. M. Diaz-Cremades, V. F. Varillas, F. La Roche, M. P. Alberiche, and A. Carrillo Differences in Cardiovascular Risk Factors, Insulin Resistance, and Insulin Secretion in Individuals With Normal Glucose Tolerance and in Subjects With Impaired Glucose Regulation: The Telde Study Diabetes Care, October 1, 2005; 28(10): 2388 - 2393. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ceriello, L. Piconi, L. Quagliaro, Y. Wang, C. A. Schnabel, J. A. Ruggles, M. A. Gloster, D. G. Maggs, and C. Weyer Effects of Pramlintide on Postprandial Glucose Excursions and Measures of Oxidative Stress in Patients With Type 1 Diabetes Diabetes Care, March 1, 2005; 28(3): 632 - 637. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ceriello Postprandial Hyperglycemia and Diabetes Complications: Is It Time to Treat? Diabetes, January 1, 2005; 54(1): 1 - 7. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |